Unión Europea - español - EMA (European Medicines Agency)

elan pharma international ltd. - natalizumab - enfermedad de crohn - inmunoestimulantes, - el tratamiento de moderada a gravemente activa la enfermedad de crohn para la reducción de signos y síntomas, y la inducción y el mantenimiento de la respuesta sostenida y la remisión, en pacientes que no han respondido a pesar de un completo y adecuado curso de la terapia con corticosteroides e inmunosupresores; o que son intolerantes o tienen contraindicaciones médicas a dichas terapias.

Unión Europea - español - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Unión Europea - español - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - esclerosis múltiple - inmunosupresores selectivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

stendhal peru s.a. - droguerÍa - natalizumab - concentrado para solucion para perfusion -  300mg/15ml - por mililitro 20.00 mg - - natalizumab

Venezuela - español - Instituto Nacional de Higiene

laboratorio eicopen c.a. - natalizumab -

Chile - español - ISPC (Instituto de Salud Pública de Chile)

biogen chile s.p.a. - natalizumab - sin formulas

Argentina - español - ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)

biogen idec argentina srl - natalizumab - solucion iny por infusion - natalizumab 300 mg / 15 ml

Unión Europea - español - EMA (European Medicines Agency)

laboratorios lesvi s.l. - fumarato de dimetilo - la esclerosis múltiple remitente-recurrente - inmunosupresores - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

novartis biosciences peru s.a. - droguerÍa - clorhidrato de fingolimod; - capsula dura - por capsula - - fingolimod